09.10.2018 • News

AkzoNobel Specialty Chemicals Relaunched as Nouryon

AkzoNobel Specialty Chemicals has been relaunched as Nouryon
AkzoNobel Specialty Chemicals has been relaunched as Nouryon

AkzoNobel's former Specialty Chemicals business has been relaunched as Nouryon. The move follows its acquisition by Carlyle and GIC, which closed on Oct. 1.

“We are starting from a great position,” said Nouryon CEO Charles Shaver. “We have a great set of businesses, leadership positions across our portfolio, long-term customer partnerships, and a dedication to continuous improvement and innovation we can leverage for further success. As an independent company we can accelerate our progress on all fronts and take our rightful place alongside other industry leaders.”

The company said the Nouryon name and brand identity reflects a history that stretches back nearly 400 years. “When we started developing our new name and brand we asked our employees what mattered most to them,” explained Vivi Hollertt, Chief Communications Officer at Nouryon. “Our employees are especially proud of our heritage, as well our track record of growing through partnerships, innovation, sustainability, and contributing to society. We combined all of this to create a brand identity for Nouryon which is true to who we are and helps us stand out from our competitors.”

Nouryon said it will be working closely with customers and other partners to innovate, make strategic investments and develop essential, sustainable solutions that meet customer needs and fuel shared growth.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read